Search Results

Orgenesis Inc. announced that Vered Caplan, CEO of Orgenesis, appeared as a guest during the “Israel Business Weekly” segment hosted by Michelle Makori and Eric Landskroner on the i24News Network.

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell Global, Inc., a contract development manufacturing organization (CDMO) subsidiary of Orgenesis backed by Great Point Partners and SFPI-FPIM.

Agreement Integrates Accellix’s Proprietary Quality Control Optic System, Cartridges, Reagents and Software into Orgenesis’ Point of Care Cellular Therapy Platform

Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59 percent 5-year CAGR of Masthercell under Orgenesis’ leadership

Orgenesis Inc. (NASDAQ: ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced that it has entered into a collaboration agreement with the John Hopkins University (“JHU”) to utilize Orgenesis’ Point-of-Care (POCare) platform to develop and supply a variety of cell and gene therapies and technologies, including cell-based immunotherapy technologies

Hemogenyx Pharmaceuticals plc announces that its wholly owned subsidiary, Hemogenyx-Cell S.A. (“Hemogenyx-Cell”) has entered into a further collaboration agreement with Orgenesis, Inc (“Orgenesis”).

Hemogenyx Pharmaceuticals plc announces that its wholly owned subsidiary Immugenyx, LLC (“Immugenyx”) has entered into a collaboration agreement with Orgenesis, Inc.

Orgenesis is developing a point-of-care manufacturing platform for cell and gene and other advanced therapies to make them more widely available and significantly more affordable.

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a developer, manufacturer and service provider of advanced cell therapies, announces that the United States Food & Drug Administration (FDA) has granted Orphan Drug designation for its Autologous Insulin Producing (AIP) cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy (TP) due to chronic pancreatitis (CP)